The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus
Open accessAbstract
Overexpression of epidermal growth factor receptor (EGFR) is observed in many cancers, sometimes accompanied by gene amplification. Recently, several clinical therapies targeting EGFR were developed, but the eligibility criteria for these therapies is not fully established. To develop such eligibility criteria for esophageal squamous cell carcinoma (ESCC), we sought to clarify: (i) the exact frequency of EGFR overexpression, (ii) the relationship between protein overexpression and gene amplification, (iii) the relationship between gene amplification and specific gene mutations and (iv) the correlation between the status of EGFR and clinical or pathological features. Immunohistochemistry revealed that EGFR protein is overexpressed in 53 (50%) of the 106 ESCC examined. Fluorescence in situ hybridization (FISH) indicated clear EGFR gene amplification in 15 of the 53 tumors, somewhat higher EGFR copy in 32 cases, and no increase in 6 cases. Gene amplification was significantly associated with high level overexpression. Direct sequencing of exons 19 and 21 of EGFR revealed no mutations in 15 tumors exhibiting gene amplification, and no mutations in 25 tumors not exhibiting gene amplification. Overexpression of EGFR was significantly correlated with depth of invasion of the tumor.In conclusion, anti‐EGFR therapies may be appropriate for patients with ESCC. We assume that combined analyses by immunohistochemistry/FISH would clarify aberrations in protein and gene function, and could help to identify those patients who may benefit from anti‐EGFR therapy. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Egner, J. R. (2010) · JAMA · doi:10.1001/jama.2010.1525 · Cited by 5,997
The 2019 WHO classification of tumours of the digestive system
Nagtegaal, I. D., Odze, R. D., Klimstra, D., Paradis, V., Rugge, M., Schirmacher, P., Washington, K. M., Carneiro, F., Cree, I. A., & the WHO Classification of Tumours Editorial Board (2020) · Histopathology · doi:10.1111/his.13975 · Cited by 4,192
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Estimates of the worldwide mortality from 25 cancers in 1990
Pisani, P., Parkin, D. M., Bray, F., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990924)83:1<18::aid-ijc5>3.0.co;2-m · Cited by 1,549
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Di Maria, M. V., Veve, R., Bremnes, R. M., Barón, A. E., Zeng, C., & Franklin, W. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.069 · Cited by 1,477
BindingDB (2025) · PubMed · doi:10.7270/q2pc374f · Cited by 924
Pisani, P., Parkin, D. M., Bray, F., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991210)83:6<870::aid-ijc35>3.0.co;2-9 · Cited by 860
Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., & Tarnawski, A. S. (2002) · Nature Medicine · doi:10.1038/nm0302-289 · Cited by 836
Wells, A. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00015-1 · Cited by 817
Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-303 · Cited by 581
Fan, Z., Baselga, J., Masui, H., et al. (1993) · PubMed · Cited by 431
Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., & Mendelsohn, J. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.16.1327 · Cited by 411
Lin, C. R., Chen, W. S., Kruiger, W., Stolarsky, L. S., Weber, W., Evans, R. M., Verma, I. M., Gill, G. N., & Rosenfeld, M. G. (1984) · Science · doi:10.1126/science.6326261 · Cited by 403
Janmaat, M. L., Kruyt, F. A. E., Rodríguez, J. A., & Giaccone, G. (2003) · PubMed · Cited by 356
Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?
Gasparini, G., Longo, R., Sarmiento, R., & Morabito, A. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01220-8 · Cited by 330
Epidermal growth factor receptor biology (IMC-C225)
Kim, E. S., Khuri, F. R., & Herbst, R. S. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00014 · Cited by 242
Nakazawa, K., Dobashi, Y., Suzuki, S., Fujii, H., Takeda, Y., & Ooi, A. (2005) · The Journal of Pathology · doi:10.1002/path.1779 · Cited by 234
Self-citationErbB-targeted therapeutic approaches in human cancer
Arteaga, C. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00104-0 · Cited by 215
Thomson, T. A., Hayes, M. M., Spinelli, J. J., Hilland, E., Sawrenko, C., Phillips, D., Dupuis, B., & Parker, R. L. (2001) · Modern Pathology · doi:10.1038/modpathol.3880440 · Cited by 214
Ooi, A., Takehana, T., Li, X., Suzuki, S., Kunitomo, K., Iino, H., Fujii, H., Takeda, Y., & Dobashi, Y. (2004) · Modern Pathology · doi:10.1038/modpathol.3800137 · Cited by 187
Self-citationEpidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies
Milas, L., Fan, Z., Andratschke, N. H., & Ang, K. K. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.08.035 · Cited by 162
Wrann, M., & Fox, C. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)86851-5 · Cited by 151
Hunts, J., Ueda, M., Ozawa, S., Abe, O., Pastan, I. H., & Shimizu, N. (1985) · PubMed · Cited by 139
Patterns of epidermal growth factor receptor amplification in malignant gliomas.
Sauter, G., MAEDA, T., Waldman, F. M., Davis, R. L., & Feuerstein, B. G. (1996) · Europe PMC (PubMed Central) · Cited by 112
Kinoshita, T., Takahashi, Y., Sakashita, T., Inoue, H., Tanabe, T., & Yoshimoto, T. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00034-7 · Cited by 92
Rosell, R., Fossella, F. V., & Milas, L. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00171-x · Cited by 39
Cited by
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Advances and challenges in the treatment of esophageal cancer
He, S., Xu, J., Liu, X., & Zhen, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.008 · Cited by 287
Application of Near-Infrared Dyes for Tumor Imaging, Photothermal, and Photodynamic Therapies
Yuan, A., Wu, J., Tang, X., Zhao, L., Xu, F., & Hu, Y. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23356 · Cited by 280
Metadata
- Authors
- Hanawa, M., Suzuki, S., Dobashi, Y., Yamane, T., Kono, K., Enomoto, N., & Ooi, A.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2005-12-20
- Volume
- 118
- Issue
- 5
- Pages
- 1173-1180
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2063867686
- Cited by
- 298
- References
- 32
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.